Last updated: 2026-09-07 09:29:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Exelixis Inc. (EXEL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $59.01, with a market capitalization of $14.62B and a P/E ratio of 16.99. Over the past 52 weeks, its price has ranged from $33.76 to $59.72. This page covers its latest market performance, valuation, price trends and company information.
$14.62B | |
$59.07 | |
$999.99 | |
$1.26 | |
$59.13 | |
1.21M | |
2.54M | |
16.99 | |
$59.72 | |
$33.76 | |
-- | |
-- |
Exelixis Inc. (EXEL) last closed at $59.13 as of 2026-09-04 23:58:00, unchanged from the previous close of $59.13.
During the latest regular trading session, EXEL traded between $1.26 and $999.99, with a volume of 1.21M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Exelixis Inc. (EXEL) moved from $55.26 to $59.01, representing a gain of 6.79% ($3.75).
The stock traded between $53.43 and $59.72 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 2.03 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 97.3%
EXEL is currently trading at $59.01, placing it 97.3% of the way from its 52-week low of $33.76 to its 52-week high of $59.72. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 1077 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Exelixis Inc. (EXEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.